FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 07/2024”.
The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.
As of the end of July 2024 we identified the following current VC trends in the United States:
- Total Healthcare & Life Sciences funding reached EUR 22,529m
- Biotech received 52% of the total investment volume (EUR 11,810m) with oncology being the leading indication (26%)
- In July Element Biosciences secures the highest transaction volume with EUR 258m, followed by Cardurion with EUR 242m and Beacon Therapeutics with EUR 158m
- ARCH Venture Partners (United States) is the most active investor (by deal volume), followed by RA Capital Management (United States) and F-Prime Capital (United States)
To access the full report, please click here.
By Mathias Klozenbücher und Johannes Link